The FDA will restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs being mass-marketed by companies as similar alternatives to FDA-approved drugs. FDA cites Hims & Hers and other compounding pharmacies in a statement(zerohedge)